Parkinson s Disease WHERE HAVE WE BEEN, WHERE ARE WE HEADING? CHARLECE HUGHES D.O.

Similar documents
10th Medicine Review Course st July Prakash Kumar

Optimizing Clinical Communication in Parkinson s Disease:

Pharmacologic Treatment of Parkinson s Disease. Nicholas J. Silvestri, M.D. Assistant Professor of Neurology

Scott J Sherman MD, PhD The University of Arizona PARKINSON DISEASE

Pharmacologic Treatment of Parkinson s Disease. Nicholas J. Silvestri, M.D. Associate Professor of Neurology

Program Highlights. Michael Pourfar, MD Co-Director, Center for Neuromodulation New York University Langone Medical Center New York, New York

PD: Key Treatment Considerations

Parkinson s Disease: initial diagnosis, initial treatment & non-motor features. J. Timothy Greenamyre, MD, PhD

Depression & Anxiety. What can I do? What are other possible treatments? What is this? Why does this happen? KEY POINTS

Evaluation and Management of Parkinson s Disease in the Older Patient

Best Medical Treatments for Parkinson s disease

Parkinson s Disease Update. Presented by Joanna O Leary, MD Movement disorder neurologist Providence St. Vincent s

Key Concepts and Issues in Parkinson s Disease in 2016

Non-Motor Symptoms of Parkinson s Disease

Parkinson s Disease Current Treatment Options

Faculty. Joseph Friedman, MD

Overview. Overview. Parkinson s disease. Secondary Parkinsonism. Parkinsonism: Motor symptoms associated with impairment in basal ganglia circuits

Parkinson s Disease Initial Clinical and Diagnostic Evaluation. J. Timothy Greenamyre, MD, PhD

Communicating About OFF Episodes With Your Doctor

PARKINSON S DISEASE. Nigrostriatal Dopaminergic Neurons 5/11/16 CARDINAL FEATURES OF PARKINSON S DISEASE. Parkinson s disease

Treatment of Parkinson s Disease: Present and Future

Appendix N: Research recommendations

Parkinson s Disease Medications: Professionals Edition

parts of the gastrointenstinal tract. At the end of April 2008, it was temporarily withdrawn from the US Market because of problems related to

Motor Fluctuations Stephen Grill, MD, PHD Parkinson s and Movement Disorders Center of Maryland and Johns Hopkins University

PARKINSON S PRIMER. Dr. Kathryn Giles MD, MSc, FRCPC Cambridge, Ontario, Canada

Medications used to treat Parkinson s disease

Any interventions, where RCTs in PD are not available, are not included in the tables.

Medication Management & Strategies When the levodopa honeymoon is over

Dr Barry Snow. Neurologist Auckland District Health Board

Prior Authorization with Quantity Limit Program Summary

Cardinal Features of Parkinson s. Management of Parkinson s Disease. Drug Induced Parkinson s. Other Parkinson s Symptoms.

10/4/2016. Disclosures. Motor symptoms are Just the tip of the iceberg. Parkinson s Disease for the Primary Care Clinician

Welcome and Introductions

Update on the Treatment of Parkinson s Disease. Neurotherapeutics for Rehab Professionals November 6 th, 2015

Movement Disorders. Eric Kraus, MD! Neurology!

Welcome and Introductions

WHAT DEFINES YOPD? HANDLING UNIQUE CONCERNS REBECCA GILBERT, MD, PHD VICE PRESIDENT, CHIEF SCIENTIFIC OFFICER, APDA MARCH 14, 2019

Evaluation of Parkinson s Patients and Primary Care Providers

PD ExpertBriefings: Parkinson s Medications: Today and Tomorrow Led By: Cynthia L. Comella, M.D., F.A.A.N.

Pharmacological treatment of Parkinson's disease

Alison Charleston 1 st September 2016

Parkinsons Disease update. Sindhu R Srivatsal MD MPH Virginia Mason Medical Center

475 GERIATRIC PSYCHOPHARMACOLOGY (p.1)

What s new for diagnosing and treating Parkinson s Disease?

PARKINS ON CENTER. Parkinson s Disease: Diagnosis and Management. Learning Objectives: Recognition of PD OHSU. Disclosure Information

Parkinson s Disease. Sirilak yimcharoen

Parkinson Disease. Lorraine Kalia, MD, PhD, FRCPC. Presented by: Ontario s Geriatric Steering Committee

Parkinson's Disease KP Update

The Role of Pharmacists in Treating & Managing Parkinson s Disease Author: Mary Jo Carden, RPh, JD Principal, Carden Associates

Psychiatric aspects of Parkinson s disease an update

Multiple choice questions: ANSWERS

Issues for Patient Discussion

PARKINSON S MEDICATION

NONE, BUT I SHOULD GET SOME

Objectives. Emerging Treatments in Parkinson s s Disease. Pathology. As Parkinson s progresses it eventually affects large portions of the brain.

The Shaking Palsy of 1817

Parkinson s Disease. Prevalence. Mark S. Baron, M.D. Cardinal Features. Clinical Characteristics. Not Just a Movement Disorder

The symptoms of the Parkinson s disease may vary from person to person. The symptoms might include the following:

Parkinson s Disease Associated Sleep Disturbance Ehsan M. Hadi, MD, MPH. Dignity Health Neurological Institute

Chapter 20. Media Directory. Amyotrophic Lateral Sclerosis. Alzheimer s Disease. Huntington s Chorea. Multiple Sclerosis

The PD You Don t See: Cognitive and Non-motor Symptoms

With Time, The Pathology of PD Spreads Throughout the Brain

Parkinson s Disease Update

Treatment of Parkinson s Disease and of Spasticity. Satpal Singh Pharmacology and Toxicology 3223 JSMBS

Drug Therapy of Parkinsonism. Assistant Prof. Dr. Najlaa Saadi PhD Pharmacology Faculty of Pharmacy University of Philadelphia

Scottish Medicines Consortium

Parkinson s disease Therapeutic strategies. Surat Tanprawate, MD Division of Neurology University of Chiang Mai

ASHI691: Why We Fall Apart: The Neuroscience and Neurophysiology of Aging. Dr. Olav E. Krigolson Lecture 5: PARKINSONS DISEASE

Parkinson s Disease. Gillian Sare

Commonly encountered medications and their side effects - what the generalist needs to know

8/28/2017. Behind the Scenes of Parkinson s Disease

Understanding Parkinson s Disease Important information for you and your loved ones

Parkinson s Disease in 60 minutes. Dr. Claire Hinnell Movement Disorder Neurologist Director Movement Disorder Clinic JPOCSC

Drugs used in Parkinsonism

Advanced Therapies for Motor Symptoms in PD. Matthew Boyce MD

Comprehensive Approach to DLB Management

Classification of Tremors. Tremor& Ac,on& Tremor& Isometric& Tremor& Rest&tremor& Parkinson s* disease* Kine,c& tremor& Task5specific& tremor&

DEMENTIA and BPSD in PARKINSON'S DISEASE. DR. T. JOHNSON. NOVEMBER 2017.

Clinical Features and Treatment of Parkinson s Disease

Movement Disorders: A Brief Overview

NICE guideline Published: 19 July 2017 nice.org.uk/guidance/ng71

Parkinson s Disease Psychosis Treatment in Long-Term Care: Clinical and Operational Considerations

9/26/18. Objectives. Disclosures. Parkinson s Disease Update Clinical and Operational Considerations

The PD You Don t See: Cognitive and Non-motor Symptoms

Drug Management of Parkinsonism. By Prof. Mohammad Saleh M. Hassan PhD. (Pharma); MSc. (Ped.); MHPE (Ed.)

Parkinson s Disease and Treatment Options for the Younger Adult

PL CE LIVE July 2015 Forum

Presented by Meagan Koepnick, Josh McDonald, Abby Narayan, Jared Szabo Mentored by Dr. Doorn

Margo J Nell Dept Pharmacology

Faculty Information 2/15/2013

History Parkinson`s disease. Parkinson's disease was first formally described in 1817 by a London physician named James Parkinson

Surgical Management of Parkinson s Disease

Parkinson s Disease and Treatment Options for the Younger Adult

Drugs Affecting the Central Nervous System

PD ExpertBriefing: What s in the Parkinson s Pipeline

Parkinson s Disease. Patients will ask you. 8/14/2015. Objectives

PUBLIC SUMMARY OFRISK MANAGEMENT PLAN

2/20/18. History of Parkinson s. What is happening in the brain? DOPAMINE! Epidemiology. Parkinson s Disease. It s much more than tremor

DRUGS THAT ACT IN THE CNS

Transcription:

Parkinson s Disease WHERE HAVE WE BEEN, WHERE ARE WE HEADING? CHARLECE HUGHES D.O.

Parkinson s Epidemiology AFFECTS 1% OF POPULATION OVER 65 MEAN AGE OF ONSET 65 MEN:WOMEN 1.5:1 IDIOPATHIC:HEREDITARY 90:10 CLINICAL SUBGROUPS (%) Tremor Dominant 8 Akinetic Rigid 26 Mixed 66

Motor and Non-Motor Symptoms of PD Primary Motor Symptoms Rest Tremor Bradykinesia Rigidity Early Non-Motor Symptoms Fatigue Depression Hyposmia Constipation REM Behavior Disorder

Motor and Non-Motor Symptoms of PD -2 Late Symptoms Treatment resistant axial sx freezing, falls, postural instability Dysphagia Psychiatric disturbances anxiety, depression, psychosis Autonomic dysfunction dizziness, drooling, nocturia, ED Cognitive impairment MCI 35% at diagnosis and 50% after 5 years Dementia - > 80% at 20 years after diagnosis

On Pt has good response to meds TERMS Common PD Terms Off Meds have worn off and PD symptoms reemerge. Motor Fluctuations - alternating between Off and On states. Dyskinesias - involuntary, non-rhythmic choreo-dystonic movements usually related to peak dopamine levels. Impulse Control Disorder - caused by DA. Pathological gambling, shopping, sexual activity, binge eating. Dopamine Dysregulation Synd compulsive overuse of dopamine meds, like an addiction impairing functioning.

Treating Early Motor Symptoms Levadopa Dopamine Agonist Provides greatest symptom control Associated with less freezing, somnolence, edema, hallucinations, and impulse control disorders than DA In older patients preferred tx due to fewer side effects Effective in early PD Less likely to cause dyskinesias Better in pts < 60 years More likely to cause impulse control disorders and hallucinations Peripheral Edema is common

Sinemet (Carbidopa/Levadopa) Carbidopa inhibits peripheral breakdown of levadopa. Levadopa converts at the BBB to dopamine 10/100, 25/100, 25/250 If taken with food, high protein diets impair absorption Taken in the waking hours is key. NOT at bedtime Start 4-5 hours apart before meals Nausea is the biggest side effect CR dosing has unreliable pharmacokinetics

Dopamine Agonist Mirapex (pramipexole), Requip (ropinirole), Neupro patch (rotigotine) Direct agonists of the dopamine system Effective monotherapy Given in waking hours 4-5 hours apart, NOT at bedtime unless treating RLS. Caution must be given about impulse control D/O

Managing Motor Flucutations MANAGING SYMPTOMS REEMERGENCE BETWEEN MEDICATION DOSES MANAGEMENT OF DYSKINESIAS

Off Time Strategies Increase the dose of dopaminergic medication Increase the time between dosing Add Comtan (catecho-o-methyltransferase inhibitor) Add Azilect (Rasagiline) OMG it s an MAO-B!!!

Comtan (catecho-o-methyltransferase inhibitor) Prolongs Levodopa serum levels allowing for increased CNS dopamine Always combine with Sinemet dosing May need to decrease Sinemet dose if dyskinesias develop Secretions turn orange 200mg dosed with each Sinemet dose Don t give with DA

Azilect (Rasagiline) A selective MAO-B inhibitor 0.5mg AM x 4 weeks, then 1mg AM Inhibits dopamine depletion in the brain. Possible neuroprotective benefit. May require dose reduction of Sinemet Avoid Flexeril, Demerol, Methadone, Dextromethorphan On SSRI pharmacist will tell your pts they will DIE No food restrictions

Management of Dyskinesias Not important to tx mild dyskinesias Develop earlier in younger patients Lower dose of Sinemet can help Decrease timing between dosing Adding Amantadine Levadopa-carbidopa intestinal gel is on the horizon

Managing Other Medication Effects NAUSEA IMPULSE CONTROL DISORDER PSYCHOSIS

Nausea Most common side effect of meds Slow GI motility is part of PD Slow titration of all meds is essential Food helps but dietary protein inhibits absorption Never give REGLAN dopamine antagonist Avoid Compazine and Phenergan

Impulse Control Disorder Usually related to DA use Hx of OCD, addictive behaviors, impulsive personality will increase risk Discuss before initiation of meds and inform S/O Can develop at any time while on DA DC meds usually resolves behaviors in 2-3 weeks Amantadine and Zonisamide may reduce symptoms in pts where behaviors persist despite removing meds

Psychosis Occur in late stage PD and as side effect of meds Initiation of DA or infections can trigger Clozapine is most effective but CBC troubles limit use in U.S. Quetiapine most used. Cyclical binding on the D2 receptor. Donepezil and Rivastigmine may help

Managing Nonmotor Symptoms REM BEHAVIOR DISORDER RESTLESS LEG SYNDROME DEPRESSION COGNITIVE IMPAIRMENT ORTHOSTATIC HYPOTENSION HYPERSALIVATION

Restless Leg Syndrome Urge to move the limbs, unpleasant, usually at night Overlap syndrome with PD Worsens with wearing off of Levadopa 30-40% of pts with iron deficiency anemia have RLS Akathisia mistaken for RLS

REM Behavior Disorder Vigorous movements during REM sleep Flailing, kicking, punching, shouting 15-50% of PD patients Usually unknown to the pt 1/3 of RBD patients develop PD Clonazepam is 1 st line therapy Melatonin option in clonazepam intolerant

Depression Very common in PD Can safely use SSRI, SNRI, or TCA Azilect (rasagilie) limits use to SSRIs at lower doses

Cognitive Impairment Cholinergic dysfunction may be partially responsible Cholinesterase inhibitors can be helpful for cognitive function, behavioral disturbances, and improved ADLs Exacerbation of tremor is a side effect GI side effects can be severe Conflicting data exists for memantine

Orthostatic Hypotension Is a manifestation of autonomic dysfunction and medication side effects Increase fluid intake, increase salt, compression stockings, slower position changes FIRST LINE Decrease blood pressure medications Midodrine, Fludrocortisone, Indomethacine

Hypersalivation Related to autonomic dysfunction Glycopyrrolate 1mg BID to TID Botulinum toxin A injections reduce saliva production parotid and submandibular injections

Melanoma and PD WHAT IS THIS ABOUT?

Melanoma PD pts have a 60% higher risk Initial reports pointed to levadopa, but now we know the risk precedes the diagnosis. LEVADOPA DOES NOT CAUSE MELANOMA

Deep Brain Stimulator THE FUTURE IS NOW!

Indications to Consider DBS Severe freezing and motor fluctuations requiring higher and higher doses of Sinemet Severe dyskinesias Younger patients (< 75) Must respond well to Sinemet No significant cognitive impairment or psychosis Mood is relatively stable

DEEP BRAIN STIMULATOR STN or GPi best for PD VIM best for ET